Detalles de la búsqueda
1.
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Brain
; 146(2): 461-474, 2023 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36256599
2.
Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Genet Med
; 25(2): 100329, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36469032
3.
Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
Mol Genet Metab
; 138(3): 107527, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36739645
4.
Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma.
Mol Genet Metab
; 133(4): 335-344, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34229967
5.
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Am J Hematol
; 96(9): 1156-1165, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34161616
6.
How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.
Mol Genet Metab
; 131(1-2): 211-218, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33012655
7.
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
Mol Genet Metab
; 129(4): 278-285, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32029355
8.
Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment.
Mol Genet Metab
; 131(1-2): 245-252, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32620536
9.
Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.
Mol Genet Metab
; 129(2): 117-124, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31924461
10.
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Blood
; 129(17): 2375-2383, 2017 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28167660
11.
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Am J Hematol
; 94(1): 29-38, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30264864
12.
A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Blood Cells Mol Dis
; 68: 185-191, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28126395
13.
Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
Mol Genet Metab
; 123(3): 347-356, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29358012
14.
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Am J Hematol
; 92(11): 1170-1176, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28762527
15.
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
JAMA
; 313(7): 695-706, 2015 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25688781
16.
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Blood Cells Mol Dis
; 77: 101-102, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31029022
17.
Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.
Skeletal Radiol
; 43(10): 1353-60, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24816856
18.
Disease progression strikingly differs in research and real-world Parkinson's populations.
medRxiv
; 2024 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38405736
19.
Disease progression strikingly differs in research and real-world Parkinson's populations.
NPJ Parkinsons Dis
; 10(1): 58, 2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38480700
20.
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Blood Cells Mol Dis
; 71: 71-74, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29680197